<div id="readability-page-1"><div><p>(MT Newswires) -- Yifan Pharmaceutical (SHE:002019) subsidiary Hefei Yifan Biological Pharmaceutical obtained drug registration from China's medical products administrator for isavuconazole sulfate for injection.</p><p> The broad-spectrum antifungal drug is used to treat infections such as aspergillosis and mucormycosis in adults, according to a filing with the Shanghai bourse.</p><p> The validity is until September 2030.</p><p>Shares of the pharmaceutical company were down 1% in recent trade.</p></div></div>

億帆醫藥

<p>（MT Newswires）-- 億帆醫藥（SHE:002019）子公司合肥億帆生物醫藥獲得中國醫療產品管理局的藥物註冊，批准注射用伊沙康唑硫酸鹽。這種廣譜抗真菌藥物用於治療成人的感染，如麴黴病和 mucormycosis。根據上海證券交易所的文件，該註冊有效期至 2030 年 9 月。該製藥公司的股票在最近的交易中下跌了 1%</p>

億帆醫藥的子公司獲得了抗真菌藥物的監管批准